Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Thoratec Scouting Cardiac Cell Delivery Catheter Applications For LVAD

This article was originally published in The Gray Sheet

Executive Summary

Thoratec's equity investment in BioCardia reflects the firm's desire to explore combination therapies in anticipation of future heart failure trends

You may also be interested in...



Financings In Brief

Digirad IPO: San Diego firm plans to use the approximately $59.7 mil. in proceeds from June 9 initial public offering to expand its nuclear cardiology business and solid-state gamma camera leasing service, rebuild its sales and marketing capabilities and repay about $9.4 mil. in debt. The offering consists of 5.5 mil. shares priced $12 each. Digirad owes Silicon Valley Bank roughly $4.8 mil. and GE Healthcare Financial Services $4.5 mil. (1"The Gray Sheet" March 29, 2004, p. 15). Joint managers for the offering were Merrill Lynch, JP Morgan Securities and Pierce, Fenner & Smith; Banc of America Securities and William Blair & Company are acting as co-managers. Digirad is listed on Nasdaq as "DRAD"...

Financings In Brief

Digirad IPO: San Diego firm plans to use the approximately $59.7 mil. in proceeds from June 9 initial public offering to expand its nuclear cardiology business and solid-state gamma camera leasing service, rebuild its sales and marketing capabilities and repay about $9.4 mil. in debt. The offering consists of 5.5 mil. shares priced $12 each. Digirad owes Silicon Valley Bank roughly $4.8 mil. and GE Healthcare Financial Services $4.5 mil. (1"The Gray Sheet" March 29, 2004, p. 15). Joint managers for the offering were Merrill Lynch, JP Morgan Securities and Pierce, Fenner & Smith; Banc of America Securities and William Blair & Company are acting as co-managers. Digirad is listed on Nasdaq as "DRAD"...

Medtronic Biotech Presence: “Pawn Or Rook?” Is VP Oesterle’s Challenge

Biologics delivery to aid organ restoration is a frontier that will permit Medtronic to advance beyond its core strengths in electromechanical implants, according to Senior VP-Medicine & Technology Stephen Oesterle

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020027

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel